Video

Evidence Around BCL2 Inhibitors for Patients with t(11;14) Translocation in MM

Author(s):

Shaji Kumar, MDJonathan L. Kaufman, MD

Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of BCL2 inhibitors for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.

Related Videos
A panel of 3 experts on CLL
A panel of 3 experts on CLL
2 KOLs are featured in this program.
2 KOLs are featured in this program.
2 KOLs are featured in this series
2 KOLs are featured in this series
2 KOLs are featured in this series
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Related Content
Erika P. Hamilton, MD
December 5th 2022

Antibody-Drug Conjugates Expand HER2+ Breast Cancer Treatment Options

Peter Gibbs, MBBS, MD, FRACP, a medical oncologist at St Vincent’s Private Hospitals and a professor at the University of Melbourne in Australia
December 5th 2022

MRD Detection Emerges as a Catalyst for Advances in Colon Cancer

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC
November 22nd 2022

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

Shaji Kumar, MD
September 1st 2022

Biomarker-Directed Therapy in Multiple Myeloma Signals the Future of the Field

Treating Patients with Gastric Cancer
August 25th 2022

Treating Patients with Gastric Cancer

Multidisciplinary Management of Patients with Basal Cell Carcinoma
August 24th 2022

Multidisciplinary Management of Patients with Basal Cell Carcinoma